Over the past 12 months, 0 insiders at REATA PHARMACEUTICALS INC filed 0 open-market SEC Form 4 transactions on RETA: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 23 | Andrea LoewenSVP, Global Regulatory Affairs | SELL | 3.2K | $172.03 | $546K |
| Sep 5, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 406 | $169.20 | $69K |
| Aug 16, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 1.8K | $168.41 | $296K |
| Aug 16, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 210 | $168.42 | $35K |
| Aug 16, 23 | Dawn Carter BirChief Commercial Officer | SELL | 398 | $168.33 | $67K |
| Aug 16, 23 | Colin John MeyerChief Innovation Officer | SELL | 596 | $168.74 | $101K |
| Aug 16, 23 | Michael D WortleyChief Legal Officer | SELL | 398 | $168.76 | $67K |
| Aug 15, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 193 | $169.06 | $33K |
| Aug 15, 23 | Dawn Carter BirChief Commercial Officer | SELL | 807 | $169.04 | $136K |
| Aug 15, 23 | Colin John MeyerChief Innovation Officer | SELL | 2.1K | $169.07 | $362K |
| Aug 15, 23 | Michael D WortleyChief Legal Officer | SELL | 807 | $169.04 | $136K |
| Jul 28, 23 | Dawn Carter BirChief Commercial Officer | SELL | 40.0K | $164.54 | $6.6M |
| Jul 28, 23 | William D. McClellan Jr.Director | SELL | 5.0K | $164.49 | $822K |
| Jul 28, 23 | Shamim RuffDirector | SELL | 8.2K | $164.53 | $1.4M |
| Jul 28, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 75.0K | $164.62 | $12.3M |
| Jun 14, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 2.3K | $102.11 | $239K |
| Jun 13, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 25.5K | $105.55 | $2.7M |
| Jun 12, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 4.7K | $99.62 | $469K |
| May 16, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 136 | $81.10 | $11K |
| May 16, 23 | Dawn Carter BirChief Commercial Officer | SELL | 417 | $80.96 | $34K |
| May 16, 23 | Samina KhanSVP, Chief Medical Officer | SELL | 352 | $81.37 | $29K |
| May 16, 23 | Colin John MeyerChief Innovation Officer | SELL | 625 | $80.94 | $51K |
| May 16, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 625 | $80.93 | $51K |
| May 16, 23 | Michael D WortleyChief Legal Officer | SELL | 417 | $80.99 | $34K |
| May 16, 23 | Andrea LoewenSVP, Global Regulatory Affairs | SELL | 313 | $81.02 | $25K |
| May 15, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 950 | $85.98 | $82K |
| May 15, 23 | Dawn Carter BirChief Commercial Officer | SELL | 894 | $85.09 | $76K |
| May 15, 23 | Samina KhanSVP, Chief Medical Officer | SELL | 288 | $85.32 | $25K |
| May 15, 23 | Colin John MeyerChief Innovation Officer | SELL | 4.5K | $85.77 | $379K |
| May 15, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 12.4K | $85.64 | $1.0M |
| May 15, 23 | Michael D WortleyChief Legal Officer | SELL | 894 | $84.81 | $76K |
| May 15, 23 | Andrea LoewenSVP, Global Regulatory Affairs | SELL | 103 | $84.71 | $9K |
| May 12, 23 | Andrea LoewenSVP, Global Regulatory Affairs | SELL | 6.8K | $86.26 | $582K |
| Mar 13, 23 | Dawn Carter BirChief Commercial Officer | SELL | 9.3K | $86.77 | $808K |
| Mar 10, 23 | Shamim RuffDirector | SELL | 5.7K | $83.73 | $481K |
| Mar 7, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 165 | $84.58 | $14K |
| Mar 7, 23 | Samina KhanSVP, Chief Medical Officer | SELL | 4.0K | $83.46 | $331K |
| Mar 7, 23 | Andrea LoewenSVP, Global Regulatory Affairs | SELL | 17.8K | $84.44 | $1.5M |
| Mar 7, 23 | Colin John MeyerChief Innovation Officer | SELL | 621 | $84.57 | $53K |
| Mar 7, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 622 | $84.70 | $53K |
| Mar 7, 23 | Michael D WortleyChief Legal Officer | SELL | 414 | $84.46 | $35K |
| Mar 7, 23 | Dawn Carter BirChief Commercial Officer | SELL | 36.0K | $86.67 | $3.1M |
| Mar 6, 23 | Dawn Carter BirChief Commercial Officer | SELL | 40.1K | $90.26 | $3.6M |
| Mar 3, 23 | Bhaskar AnandSVP, Chief Accounting Officer | SELL | 820 | $87.47 | $72K |
| Mar 3, 23 | Dawn Carter BirChief Commercial Officer | SELL | 2.2K | $88.25 | $191K |
| Mar 3, 23 | Manmeet Singh SoniCOO, CFO and President | SELL | 3.6K | $87.97 | $316K |
| Mar 3, 23 | Michael D WortleyChief Legal Officer | SELL | 2.2K | $87.57 | $190K |
| Mar 3, 23 | Samina KhanSVP, Chief Medical Officer | SELL | 2.8K | $87.36 | $246K |
| Mar 3, 23 | Andrea LoewenSVP, Global Regulatory Affairs | SELL | 1.6K | $87.73 | $140K |
| Mar 3, 23 | Colin John MeyerChief Innovation Officer | SELL | 5.3K | $87.35 | $462K |
Over the past 12 months, insiders at REATA PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 0 sales worth $0 on RETA, which makes them mixed over the period. The most recent Form 4 was filed on .
0 different insiders at REATA PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on RETA over the last 12 months.
InsiderTape plots every RETA insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every REATA PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →